Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Formulation Development and Characterization of Darunavir and Ritonavir Immediate Release Tablets using Quality by Design approach
View through CrossRef
Darunavir is a nonpeptidic inhibitor of protease and is primarily metabolized by cytochrome P450 3A (CYP3A) isoenzymes. It is usually Coad ministered with low-dose ritonavir (Darunavir/r). Ritonavir is an inhibitor of CYP3A isoenzymes and pharmacologically enhances Darunavir which leads to increased plasma concentrations of darunavir and allows for daily lower dose. Here, we have developed combination IR formulation of Darunavir and Ritonavir and evaluated. In vitro drug release of all formulations was carried out in dissolution medium 900ml of pH 3.0 0.05 M Sodium Phosphate Buffer + 2% Tween 20 for 75 Min USP II apparatus (paddle). The results shown that, all the formulations of matrix tablets shown the good release of drug from trialed formulations however all formulations were not releasing the drug in enough amount. In matrix tablets F8, the release of drug shows 99%. So, the formulation F8 has been considered as suitable for the immediate release of Darunavir and Ritonavir. Tablets were also evaluated for physic chemical properties, dissolution studies and though Quality by Design (QbD) method.
A and V Publications
Title: Formulation Development and Characterization of Darunavir and Ritonavir Immediate Release Tablets using Quality by Design approach
Description:
Darunavir is a nonpeptidic inhibitor of protease and is primarily metabolized by cytochrome P450 3A (CYP3A) isoenzymes.
It is usually Coad ministered with low-dose ritonavir (Darunavir/r).
Ritonavir is an inhibitor of CYP3A isoenzymes and pharmacologically enhances Darunavir which leads to increased plasma concentrations of darunavir and allows for daily lower dose.
Here, we have developed combination IR formulation of Darunavir and Ritonavir and evaluated.
In vitro drug release of all formulations was carried out in dissolution medium 900ml of pH 3.
0 0.
05 M Sodium Phosphate Buffer + 2% Tween 20 for 75 Min USP II apparatus (paddle).
The results shown that, all the formulations of matrix tablets shown the good release of drug from trialed formulations however all formulations were not releasing the drug in enough amount.
In matrix tablets F8, the release of drug shows 99%.
So, the formulation F8 has been considered as suitable for the immediate release of Darunavir and Ritonavir.
Tablets were also evaluated for physic chemical properties, dissolution studies and though Quality by Design (QbD) method.
Related Results
Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV
Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV
ABSTRACT
Ritonavir is important in antiretroviral therapy (ART) because it is used to
boost the ...
Darunavir: Pharmacokinetics and Drug Interactions
Darunavir: Pharmacokinetics and Drug Interactions
Darunavir (TMC114) is a new HIV protease inhibitor that has demonstrated substantial antiretroviral activity against wild-type HIV-1 virus and multidrug-resistant strains. Darunavi...
The HIV-Protease Inhibitor Ritonavir(Norvir®) Is Active Against Human AML Blasts In Vitro and In Vivo and Has Synergistic Cytotoxic Activity with the Proteaseome Inhibitor Bortezomib (Velcade®).
The HIV-Protease Inhibitor Ritonavir(Norvir®) Is Active Against Human AML Blasts In Vitro and In Vivo and Has Synergistic Cytotoxic Activity with the Proteaseome Inhibitor Bortezomib (Velcade®).
Abstract
Upregulation of alternative proteolytic pathways characterizes malignant cells that overcome proteasome inhibition in vitro. The proteasome inhibitor Bortez...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
EVALPAX: Evaluation of a pharmacist-driven protocol for nirmatrelvir/ritonavir prescribing in a community hospital system
EVALPAX: Evaluation of a pharmacist-driven protocol for nirmatrelvir/ritonavir prescribing in a community hospital system
Abstract
Purpose
The purpose of this study was to evaluate pharmacist prescribing of nirmatrelvir/ritonavir to ensure thi...
Effects of ritonavir‐boosted darunavir vs. ritonavir‐boosted atazanavir on lipid and glucose parameters in HIV‐negative, healthy volunteers
Effects of ritonavir‐boosted darunavir vs. ritonavir‐boosted atazanavir on lipid and glucose parameters in HIV‐negative, healthy volunteers
BackgroundDarunavir (TMC114) is a new HIV protease inhibitor (PI).DesignThis Phase I, randomized, open‐label trial compared the effects of darunavir plus low‐dose ritonavir (RTV) (...
Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
AbstractBackground: Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the conte...
Comparison of Total Hemispherical Reflectance and Emittance Values Between Metformin Extended-Release Tablets Stored Under Ambient and Stress Conditions
Comparison of Total Hemispherical Reflectance and Emittance Values Between Metformin Extended-Release Tablets Stored Under Ambient and Stress Conditions
Type 2 diabetes is a serious health problem worldwide. Metformin as the first-line drug in diabetes treatment mainly inhibits glucose production in the liver. Diabetes is often acc...